TEVOGEN BIO
Biotechnology Research
Warren, New Jersey 2,927 followers
Specialty immunotherapy biotech developing off-the-shelf precision T cell therapeutics in oncology, neurology, virology.
About us
Tevogen Bio brings together a highly skilled team of preeminent scientists, senior biopharmaceutical leaders, and manufacturing experts with the goal of advancing global health. The company’s patient centric mission is to leverage its proprietary cell and gene therapy platforms and novel business model to rapidly innovate breakthrough immunotherapies for cancers and viral infections with high unmet need. Tevogen Bio’s foundational vision is a healthier world through equitable access to lifesaving innovations.
- Website
-
http://www.tevogen.com
External link for TEVOGEN BIO
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Warren, New Jersey
- Type
- Privately Held
- Founded
- 2020
Locations
-
Primary
15 Independence Blvd
Warren, New Jersey 07059, US
Employees at TEVOGEN BIO
-
Sadiq Khan
Chief Commercial Officer @ Tevogen Bio
-
Ryan Saadi, MD, MPH
TEVOGEN BIO Founder, Chair and Chief Executive Officer (Tevogen Bio Holdings Inc. is a Nasdaq listed public company. Stock symbol: TVGN)
-
Victor Sordillo
Managing Director - Risk Advisory Services - Verita CSG, Inc. and Board of Directors at Tevogen Bio
-
Dolores Grosso
Clinical Research Lead
Updates
-
🔗Link: https://lnkd.in/g5BvPeSF “I commend Tevogen’s leadership for steering the company’s remarkable growth strategy. With over three decades in this sector, I see Tevogen’s significant achievements since inception as a testament to the strength of our efficient business model. While excessive dilution at public listing, leaving founding teams with around 5% ownership, is common, Tevogen stands apart with 78% ownership intact. As we pursue ambitious growth, equity-based financing must never be an option. You can't make a difference without being different.” - Ryan Saadi, MD, MPH #TVGN #affordable #accessible #celltherapy #biotech
-
Link: https://lnkd.in/gErwNSYp · Improved operating performance by reducing net loss by $52.5 million; reported net loss of $4.3 million and $56.8 million for the nine months ended September 30, for 2024 and 2023, respectively. · Significantly improved financial position by eliminating nearly all of its liabilities; reported $10.5 million as of September 30, 2024, and $99.9 million as of December 31, 2023. · $10 billion+, representing Tevogen’s IP and product assets based on internal discounted cash flow models, is not reflected on the company balance sheet. Similarly, Tevogen’s AI assets, a critical component of its innovation platform, remain unreported on company balance sheet. · Sufficient available capital to fund operations for the next 33 months, supported by a loan agreement. · Approximately 78% of equity retained by Tevogen officers. #TVGN #affordable #accessible #celltherapy #biotech TEVOGEN BIO
-
TEVOGEN BIO reposted this
TEVOGEN BIO Founder, Chair and Chief Executive Officer (Tevogen Bio Holdings Inc. is a Nasdaq listed public company. Stock symbol: TVGN)
The pursuit of developing complex personalized medicines for large patient populations is merely an audacious goal for a fortunate Yale Citizen, but rather an intellectual pursuit, a call of duty to serve that cannot be ignored. Each member of TEVOGEN BIO understands that the question is not "why me?" but rather "if not me, then who?" “And because a Yale education is a great privilege, it comes with certain obligations. I want to speak today about some of the most important obligations of Yale citizenship. I will delineate four of them - Peter Salovey, President of Yale University, August 25, 2018. - The responsibility to be curious, constantly; - The duty to listen to others, even those whose thoughts you despise, and to exchange ideas freely; - The obligation to create a culture of respect here; - And the requirement to use the gifts you have been provided to serve others and the world.” ➡️https://lnkd.in/ea3zgHuA Tevogen Bio: https://lnkd.in/eqivAh4M #Gratitude #Enlightenment #biotech 🧬 TEVOGEN.COM
-
Link: https://lnkd.in/gDT8Y_fh · Since its founding in 2020, Tevogen Bio has developed a significant asset portfolio, and kept expenditures under $40 million, a fraction of the industry norm. · Tevogen’s success would not be possible without its passionate team united by a common vision. · Founders must navigate the need for capital to fuel growth with a vigilant eye on avoiding equity dilution. · Our financing options must consider preserving shareholder value and the potential equity dilution of warrant conversion at a strike price of $11.50 per share. #TVGN #affordable #accessible #celltherapy #biotech
-
"Transient quick wins or impressive numbers may give the illusion of success, but true success is sustainable and cannot be achieved without bringing everyone on the journey — be it a company or an entire society. Aim to create a lasting impact that leaves no one behind; success will follow." - Ryan Saadi, MD, MPH, Boy Scouts of America STEM Award acceptance speech #TVGN #affordable #accessible #celltherapy #biotech
-
We mourn, we honor, and we uphold the values our heroes cherished more than life itself. The ideals of America live on because of the men and women who defend them. #TVGN #VeteransDay TEVOGEN BIO Ryan Saadi, MD, MPH
-
TEVOGEN BIO reposted this
TEVOGEN BIO Founder, Chair and Chief Executive Officer (Tevogen Bio Holdings Inc. is a Nasdaq listed public company. Stock symbol: TVGN)
Tevogen Meets Wall Street: A Shared Vision of Health and Prosperity TEVOGEN.COM
-
Link: https://lnkd.in/gbaXS6s2 Kirti Desai (Cpa), Tevogen Bio’s Chief Financial Officer, commented, “As we prepare to file our most recent quarterly financials, I want to highlight that Tevogen Bio has the funding it needs to sustain its operations and continue executing our strategy. We remain attentive to enhancing shareholder value, which is always top of mind for our team as we work to drive long-term success.” #TVGN #affordable #accessible #celltherapy #biotech